| 2016-10-11 08:59:03|
DCTH 08:59 10/11 10/11/16
Delcath Systems announces new U.S. clinical sites for FOCUS Phase 3 trial
Delcath Systems announces that five new clinical trial sites in the U.S. have been activated in the Company's global FOCUS Phase 3 clinical trial for patients with hepatic dominant ocular melanoma. These accredited centers join several other prestigious centers as active participants in the FOCUS Trial. Currently, Delcath now has a total of 8 cancer centers in the U.S. open for patient enrollment in the FOCUS Trial. The new participating centers are: Ohio State University Comprehensive Cancer Center; MD Anderson Cancer Center; Thomas Jefferson University; Sidney Kimmel Cancer Center; University of Chicago Comprehensive Cancer Center; University of Maryland Greenebaum Cancer Center.